In vivo CAR cell therapy: from bench to bedside

Area of Science:

• Immunotherapy
• Cellular Therapy
• Oncology

Background:

• Chimeric antigen receptor T cell (CAR-T) therapy is effective for hematological malignancies.
• Current autologous ex vivo CAR-T manufacturing is complex, costly, and time-consuming.
• This limits patient access to this life-saving treatment.

Purpose of the Study:

• To review the latest advancements in in vivo CAR-T cell therapies.
• To explore the transition from laboratory research to clinical application.
• To identify strategies for improving the clinical translation of in vivo CAR-T.

Main Methods:

• Review of current scientific literature on in vivo CAR-T therapy.
• Analysis of preclinical and clinical research progress.
• Synthesis of findings from bench to bedside.

Main Results:

• In vivo CAR-T therapy directly reprograms endogenous T cells in situ.
• This method bypasses the need for apheresis and ex vivo cell manufacturing.
• It presents a more efficient, economical, and accessible therapeutic model.

Conclusions:

• In vivo CAR-T therapy represents a significant paradigm shift in cell therapy.
• This approach moves CAR-T towards a "ready-to-use" therapeutic product.
• Further research is crucial for advancing clinical translation and patient accessibility.